{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:51:34Z","timestamp":1777647094253,"version":"3.51.4"},"reference-count":14,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,12,30]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>A woman in her 80s was brought to the emergency department for acute onset of generalised weakness, lethargy and altered mental state. The emergency medical service found her to have symptomatic bradycardia, and transcutaneous pacing was done. Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation. On arrival at the hospital, she was found to have marked bradycardia with widened QRS, hyperglycaemia and metabolic acidosis. Transvenous pacing along with pressor support and insulin were initiated, and she was admitted to the intensive care unit. Drug interaction between ritonavir-boosted nirmatrelvir and verapamil leading to verapamil toxicity was suspected of causing her symptoms, and both drugs were withheld. She reverted to sinus rhythm on the fourth day, and the pacemaker was discontinued.<\/jats:p>","DOI":"10.1136\/bcr-2022-252677","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T10:27:38Z","timestamp":1673605658000},"page":"e252677","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8396-7019","authenticated-orcid":false,"given":"Obaid Imtiyazul","family":"Haque","sequence":"first","affiliation":[{"name":"Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA"},{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Mahar","sequence":"additional","affiliation":[{"name":"Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sloane","sequence":"additional","affiliation":[{"name":"Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"2025082711503333000_16.1.e252677.1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J Clin Hypertens"},{"key":"2025082711503333000_16.1.e252677.2","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-021-01131-y","article-title":"Drug interactions with antihypertensives","volume":"23","author":"Fravel","year":"2021","journal-title":"Curr Hypertens Rep"},{"key":"2025082711503333000_16.1.e252677.3","unstructured":"Ritonavir-Boosted Nirmatrelvir (Paxlovid) . COVID-19 treatment guidelines. Available: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antiviral-therapy\/ritonavir-boosted-nirmatrelvir-paxlovid-\/ [Accessed 22 Aug 2022]."},{"key":"2025082711503333000_16.1.e252677.4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bcp.12763","article-title":"Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies","volume":"81","author":"Graudins","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025082711503333000_16.1.e252677.5","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000278916.04569.23"},{"key":"2025082711503333000_16.1.e252677.6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2710.2012.01352.x","article-title":"Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia","volume":"37","author":"Hegazi","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2025082711503333000_16.1.e252677.7","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267319.18123.d3"},{"key":"2025082711503333000_16.1.e252677.8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MJT.0b013e31824d5fbd","article-title":"Hyperinsulin therapy for calcium channel antagonist poisoning: a seven-year retrospective study","volume":"20","author":"Espinoza","year":"2013","journal-title":"Am J Ther"},{"key":"2025082711503333000_16.1.e252677.9","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1097\/CCM.0000000000002087","article-title":"Experts consensus recommendations for the management of calcium channel blocker poisoning in adults","volume":"45","author":"St-Onge","year":"2017","journal-title":"Crit Care Med"},{"key":"2025082711503333000_16.1.e252677.10","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.965827"},{"key":"2025082711503333000_16.1.e252677.11","unstructured":"PAXLOVIDTM . Paxlovid (nirmatrelvir and ritonavir). Kirkland, Quebec, Canada Pfizer Canada ULC; 2022 [Accessed 5 December 2022]."},{"key":"2025082711503333000_16.1.e252677.12","unstructured":"WHO coronavirus (COVID-19) Dashboard. Available: https:\/\/covid19.who.int [Accessed 5 December 2022]."},{"key":"2025082711503333000_16.1.e252677.13","unstructured":"Cascella M , Rajnik M , Aleem A . Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2022. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/"},{"key":"2025082711503333000_16.1.e252677.14","unstructured":"CDC . People with certain medical conditions. Centers for Disease Control and Prevention, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-252677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:50:39Z","timestamp":1756320639000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-252677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,13]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/bcr-2022-252677"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-252677","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}